← Leaderboards
Jianjun Chen
Beckman Research Institute/City Of Hope
$21,393,583
Attributed
$21,864,482
Total exposure
12
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,864,482 · 12
By mechanism
R01$20,822,684 · 10
U01$941,798 · 1
R56$100,000 · 1
Top collaborators
- Xiaolan Deng1 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Chun-Wei David Chen$8,071,175
Others in their field
Top investigators on “Play”
- Lawrence Corey · Fred Hutchinson Cancer Center$428,785,907
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$200,435,757
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Jeffrey P Krischer · University Of South Florida$191,869,794
- Constance Ann Benson · University Of California, San Diego$187,132,366
Research focus
PlayReportingMolecularLeukemiaOverexpressionLeadPathogenesisHematopoietic NeoplasmsSuccessIn VivoAcute Myelocytic LeukemiaMaintenanceModificationMalignant NeoplasmsResearch DesignCellsFlt3 GeneOncogenicGenesIn VitroPathway InteractionsSelf-RenewalBasic ScienceBone Marrow Transplantation
Grant awards (51)
Mechanism and therapeutic implication of RNA-modification-mediated codon-biased translation in acute myeloid leukemia$941,798
U01 · FY2025 · CA · contact PI
TET2-mediated epitranscriptomic regulation in leukemia microenvironment$684,584
R01 · FY2025 · CA · contact PI
The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia$573,809
R01 · FY2025 · CA · contact PI
TET2-mediated epitranscriptomic regulation in leukemia microenvironment$650,167
R01 · FY2024 · CA · contact PI
The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia$544,938
R01 · FY2024 · CA · contact PI
Targeting FTO to treat acute myeloid leukemia$542,055
R01 · FY2024 · CA · contact PI
TET2-mediated epitranscriptomic regulation in leukemia microenvironment$684,230
R01 · FY2023 · CA · contact PI
The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia$562,052
R01 · FY2023 · CA · contact PI
Targeting FTO to treat acute myeloid leukemia$558,632
R01 · FY2023 · CA · contact PI
The function and underlying mechanism of TET1 in myelodysplastic syndromes$548,659
R01 · FY2023 · DK · contact PI
The role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AML$450,915
R01 · FY2023 · CA · contact PI
The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia$573,508
R01 · FY2022 · CA · contact PI
Targeting FTO to treat acute myeloid leukemia$558,898
R01 · FY2022 · CA · contact PI
The function and underlying mechanism of TET1 in myelodysplastic syndromes$554,854
R01 · FY2022 · DK · contact PI
The role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AML$450,740
R01 · FY2022 · CA · contact PI
Targeting FTO to treat acute myeloid leukemia$569,941
R01 · FY2021 · CA · contact PI
The function and underlying mechanism of TET1 in myelodysplastic syndromes$559,500
R01 · FY2021 · DK · contact PI
The role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AML$459,851
R01 · FY2021 · CA · contact PI
Targeting TET1 signaling to treat acute myeloid leukemia$457,310
R01 · FY2021 · CA · contact PI
The role and mechanism of FTO in leukemogenesis and drug response$426,319
R01 · FY2021 · CA · contact PI
Targeting FTO to treat acute myeloid leukemia$569,670
R01 · FY2020 · CA · contact PI
The function and underlying mechanism of TET1 in myelodysplastic syndromes$564,921
R01 · FY2020 · DK · contact PI
The role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AML$459,843
R01 · FY2020 · CA · contact PI
Targeting TET1 signaling to treat acute myeloid leukemia$457,310
R01 · FY2020 · CA · contact PI
The role and mechanism of FTO in leukemogenesis and drug response$426,319
R01 · FY2020 · CA · contact PI
The role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AML$459,919
R01 · FY2019 · CA · contact PI
Targeting TET1 signaling to treat acute myeloid leukemia$443,591
R01 · FY2019 · CA · contact PI
The role and mechanism of FTO in leukemogenesis and drug response$413,529
R01 · FY2019 · CA · contact PI
Targeting TET1 signaling to treat acute myeloid leukemia$475,560
R01 · FY2018 · CA · contact PI
The role and mechanism of FTO in leukemogenesis and drug response$444,571
R01 · FY2018 · CA · contact PI
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemia$392,355
R01 · FY2018 · CA · contact PI
The role and functional mechanism of TET1 in MLL-rearranged leukemia$369,725
R01 · FY2018 · CA · contact PI
The role, mechanism and therapeutic potential of TET1 in MDS$100,000
R56 · FY2018 · DK · contact PI
Targeting TET1 signaling to treat acute myeloid leukemia$430,865
R01 · FY2017 · CA · contact PI
The role and mechanism of FTO in leukemogenesis and drug response$389,933
R01 · FY2017 · CA · contact PI
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemia$336,114
R01 · FY2017 · CA · contact PI
The role and functional mechanism of TET1 in MLL-rearranged leukemia$291,658
R01 · FY2017 · CA · contact PI
The role and functional mechanism of TET1 in MLL-rearranged leukemia$37,105
R01 · FY2017 · CA · contact PI
The role and mechanism of FTO in leukemogenesis and drug response$29,948
R01 · FY2017 · CA · contact PI
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemia$336,114
R01 · FY2016 · CA · contact PI
The role and functional mechanism of TET1 in MLL-rearranged leukemia$327,850
R01 · FY2016 · CA · contact PI
The role and functional mechanism of TET1 in MLL-rearranged leukemia$342,579
R01 · FY2015 · CA · contact PI
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemia$318,441
R01 · FY2015 · CA · contact PI
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemia$10,281
R01 · FY2015 · CA · contact PI
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemia$343,222
R01 · FY2014 · CA · contact PI
The role and functional mechanism of TET1 in MLL-rearranged leukemia$324,194
R01 · FY2014 · CA · contact PI
The role and functional mechanism of a miRNA cluster, mir-17-92 in leukemogenesis$278,061
R01 · FY2012 · CA · contact PI
The role and functional mechanism of a miRNA cluster, mir-17-92 in leukemogenesis$278,061
R01 · FY2011 · CA · contact PI
The role and functional mechanism of a miRNA cluster, mir-17-92 in leukemogenesis$286,661
R01 · FY2010 · CA · contact PI
The role and functional mechanism of a miRNA cluster, mir-17-92 in leukemogenesis$286,661
R01 · FY2009 · CA · contact PI
The role and functional mechanism of a miRNA cluster, mir-17-92 in leukemogenesis$286,661
R01 · FY2008 · CA · contact PI